Is your company listed among the best pharma/biotech workplaces?
New Hampshire law barring use of prescription data declared unconstitutional – very important ruling in the ongoing tussle about access to physician-prescribing information.
Encouraging first quarter results: Cephalon, Celgene, Biogen-Idec.
Good news for Pfizer and Eisai: new indication for Fragmin.
Rituxin and MS – promising results.
Long-ish, but interesting article on how Merck pushed the envelope to win the race, bringing the first DPP-4 inhibitor (Januvia) to the market.
Very exciting advance (3-drug cocktail) for treating HER2-positive breast cancer.
Novartis’ Diovan racks up another impressive study result; dramatic reduction in stroke and cardiovascular events.
On the device front, Zimmer gets major growth out of knee implants targeted toward women.
Just in: four former Serono sales execs acquitted in major kickback case.
Late-breaking, and fascinating news from the world of genetics: isolating genome variations (DNA kinks) that are strongly tied to heart disease.
Leave a Reply